文章：

阿特珠单抗联合贝伐珠单抗治疗后早期IL-10与TNF-α水平升高可预测晚期肝细胞癌患者生存期：一项前瞻性队列研究

An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study

原文发布日期：21 October 2024

DOI: 10.3390/cancers16203543

类型: Article

开放获取: 是

英文摘要：

Background/Objectives: Reliable biomarkers for predicting outcomes in hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Ate/Bev) are still lacking. Cytokines, which play a crucial role in immune regulation and HCC progression, have potential as predictive markers, but data supporting their use are limited. This study aimed to evaluate the impact of early changes in cytokine levels on the clinical outcomes of advanced HCC patients.Methods: We prospectively enrolled 32 advanced HCC patients, collecting blood samples before the first and second Ate/Bev treatments. These samples were analyzed for IL-2, IL-6, IL-10, IL-12, IL-17, IFN-γ, and TNF-α levels to assess changes post-treatment. The primary outcome was overall survival, with a secondary focus on progression-free survival (PFS) at 6 months.Results: The mean age of the participants was 64.2 years, with the majority being male (93.8%). Patients showing increased IL-10, IL-17, and TNF-α levels had significantly better survival (p< 0.05) and marginally improved PFS compared to those with decreased cytokine levels. Interestingly, a positive correlation was noted between changes in IL-10 and TNF-α levels (p= 0.009). Furthermore, a multivariable analysis revealed that increased levels of IL-10 and TNF-α were significant predictors of enhanced survival (hazard ratio, 0.07; 95% confidence interval, 0.01–0.46;p= 0.005).Conclusions: An early increases in IL-10 and TNF-α after Ate/Bev treatment may serve as effective biomarkers for clinical outcomes in advanced HCC patients.

摘要翻译： 

背景/目的：目前尚缺乏可靠的生物标志物来预测阿特珠单抗联合贝伐珠单抗（Ate/Bev）治疗肝细胞癌（HCC）的预后。细胞因子在免疫调节和HCC进展中起关键作用，具有作为预测标志物的潜力，但支持其应用的数据有限。本研究旨在评估细胞因子水平早期变化对晚期HCC患者临床结局的影响。方法：我们前瞻性纳入32例晚期HCC患者，在首次和第二次Ate/Bev治疗前采集血样。检测样本中IL-2、IL-6、IL-10、IL-12、IL-17、IFN-γ和TNF-α水平以评估治疗后的变化。主要结局指标为总生存期，次要关注点为6个月无进展生存期（PFS）。结果：参与者平均年龄64.2岁，男性占93.8%。与细胞因子水平下降的患者相比，IL-10、IL-17和TNF-α水平升高的患者生存期显著改善（p<0.05），PFS也有边际性提升。值得注意的是，IL-10与TNF-α水平变化呈正相关（p=0.009）。多变量分析进一步显示，IL-10和TNF-α水平升高是生存期改善的显著预测因子（风险比0.07；95%置信区间0.01–0.46；p=0.005）。结论：Ate/Bev治疗后早期IL-10和TNF-α水平升高可能成为晚期HCC患者临床结局的有效生物标志物。

原文链接：

An Early Increase in IL-10 and TNF-α Levels Following Atezolizumab Plus Bevacizumab Treatment Predicts Survival in Advanced Hepatocellular Carcinoma Patients: A Prospective Cohort Study